The Fed cut rates. Biotech didn’t notice.
Summarize this article with:
Site SearchClearSEARCHAdvanced Search ➔Search ResultsSymbolsNo results foundAll NewsArticlesVideoPodcasts0 ResultsNo Results FoundAuthorsNo results foundSectionsNo results foundColumnsNo results found Outside the BoxOpinion: The Fed cut rates. Biotech didn’t notice.Biotechs are instead spending their time advancing the kind of smart science that will catch the eye of cash-rich pharmaceutical companiesPublished: Dec. 10, 2025 at 5:06 p.m. ETShareResizeOne popular biotech ETF was up about 1% after the Federal Reserve announced its third interest-rate cut for the year. Photo: Getty ImagesThe Federal Reserve cut interest rates as expected — but for the biotech sector, it was just another Wednesday. While the general market celebrates cheaper liquidity, the real determinant of the next wave of biotech leaders is the concentration of capital. We are leaving fragmented competition for the era of oligopoly. Show Conversation (0)Back To TopCopyright © 2025 MarketWatch, Inc. All rights reserved.Terms of UsePrivacy NoticeCookie NoticeArchive MarketWatchCustomer CenterContact UsNewsroom RosterVirtual Stock ExchangeMarketWatch GuidesCopyright PolicyManage NotificationsCancel My SubscriptionCompanyDow JonesCode of ConductCorrectionsReprints & LicensingDigital Self ServiceYour Ad ChoicesCorporate SubscriptionsAccessibilityDow Jones NetworkThe Wall Street JournalBarron'sInvestor's Business DailyFinancial News Londonrealtor.comMansion GlobalDow Jones Smart MoneyIntraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.